Trastunix
Generic Name
Trastuzumab
Manufacturer
Generic Pharmaceutical Co. (example)
Country
Various
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| trastunix 440 mg injection | ৳ 58,005.00 | N/A |
Description
Overview of the medicine
Trastuzumab is a humanized monoclonal antibody used to treat certain types of HER2-positive breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. It targets and binds to the HER2 protein, which is overexpressed in these cancers, thereby inhibiting tumor cell growth.
Uses & Indications
Dosage
Adults
Loading dose: 4 mg/kg IV over 90 minutes, followed by weekly maintenance doses of 2 mg/kg IV over 30 minutes. Or, 8 mg/kg IV over 90 minutes once every 3 weeks, followed by maintenance doses of 6 mg/kg IV over 30-90 minutes once every 3 weeks. Dosage varies based on indication and concomitant chemotherapy.
Elderly
No specific dose adjustments needed based solely on age; however, monitor for cardiac function more closely.
Renal_impairment
No specific dose adjustments required for mild to moderate renal impairment. Data for severe impairment is limited.
How to Take
Administer intravenously via infusion pump. Do NOT administer as an intravenous push or bolus. The initial dose should be infused over 90 minutes. Subsequent doses can be infused over 30 minutes if the initial infusion was well-tolerated.
Mechanism of Action
Trastuzumab binds to the extracellular domain of the HER2 protein, inhibiting HER2-mediated signaling pathways, inducing antibody-dependent cell-mediated cytotoxicity (ADCC), and inhibiting angiogenesis. This combined action leads to inhibition of tumor cell proliferation and survival.
Pharmacokinetics
Onset
Therapeutic effects typically observed after several weeks of continuous treatment.
Excretion
Degraded into small peptides and amino acids; not primarily eliminated via renal or hepatic routes.
Half life
Approximately 28 days (ranging from 1.5 to 30 days, dose-dependent).
Absorption
Administered intravenously, resulting in complete systemic availability.
Metabolism
Catabolism of IgG, primarily via intracellular degradation.
Side Effects
Contraindications
- •Known hypersensitivity to trastuzumab or any excipients.
- •Patients with severe, uncontrolled cardiac dysfunction.
Drug Interactions
Paclitaxel
May increase serum concentrations of trastuzumab when given sequentially.
Anthracyclines
Increased risk of cardiotoxicity when co-administered with anthracyclines.
Other cardiotoxic agents
Caution advised due to potential for additive cardiac effects.
Storage
Store unopened vials refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Reconstituted solution should also be stored refrigerated.
Overdose
There is no specific antidote for trastuzumab overdose. In clinical trials, no cases of overdose have been reported. Management should involve supportive care and close monitoring for adverse reactions.
Pregnancy & Lactation
Pregnancy Category D. Trastuzumab can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Breastfeeding is not recommended due to potential harm to the infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years when stored unopened. Reconstituted solution is stable for 28 days under refrigeration.
Availability
Hospitals, Specialized Oncology Centers
Approval Status
FDA Approved
Patent Status
Patent expired for biosimilar versions
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in